To test or not to test: exploring why service users of a large e-sexual health service (e-SHS) don't return blood samples for sexually transmitted infection (STI) testing



Dr Sara Day¹, Dr Sean Perera² Mr Ryan Kinsella³, Mr Tim Alston³

NHS Foundation Trust







Background

Methods

E-SHS have expanded access to STI testing. Many involve home-sampling of capillary blood for blood-borne virus screening (BBVS). Sexual Health London (SHL) is a large e-SHS that serves residents of 30 London boroughs and has received >900,000 kit orders since its launch in 2018. SHL postal kits routinely include blood sampling components. We explore why our service users do not return their blood sample for testing.

Between 03 11 20-01 12 20 all SHI service users ordering a kit were invited to complete an optional e-survey, enquiring about their intention to return a blood sample. We report the survey responses, kit/blood returns and whether a successful BBVS result was obtained from returned blood samples.

Results

There were 65231 kit orders during the survey period and 19030 (29.2%) responded to the survey. 78.3% reported intention to return a blood sample, 11.0% stated they might do and would decide when the kit arrived. 10.7% of users reported no intention and cited the following reasons: perceived difficulty in the blood-sampling process (42.5%, 865/2036; already tested recently elsewhere (23.1%, 470/2036; didn't feel they were at risk (22.2%, 452/2036). Table 1.

Survey respondents were just as likely to return a kit than non-respondents: 14501/19030 (76.2%) vs 34205/46201 (74.0%) (OR 1.12 95% CI 1.08-1.17, p< 0.0001) but more likely to return a kit inclusive of blood, than survey nonrespondents: 12152/14501 (83.8%) vs 22146/34205 (64.7%) (OR 2.82 95% CI 2.68-2.96, p<0.0001). Blood returns from survey respondents who intended to return their blood were more likely to obtain a valid BBVS result, than blood returns from those without intention (OR 2.38 95% CI 1.90-2.97, P<0.0001). Failure to obtain a BBVS result is usually because of sample haemolysis or an insufficient volume returned.



STI positivity was similar amongst users regardless of their intention to return a blood sample

Table I. Survey and e-SHS outcomes for survey respondents

	er's intention to urn blood sample	Orders (%)		Blood returns / kit returns (%)		Achieved BBVS result from blood returns (%)		Chlamydia / Gonorrhoea Positive (%)		Syphilis or BBV reactive (%)	
Yes	5	14897	(78.3)	10810/11498	(94.0)	9300	(86.0)	677	(5.6)	436	(4.4)
Ма	ybe	2097	(11)	929/1487	(62.5)	716	(77.1)	88	(5.6)	26	(3.4)
No	(any reason):	2036	(10.7)	413/1516	(27.2)	298	(72.2)	119	(7.4)	18	(5.5)
	Recently tested	470	(2.5)	86/371	(23.2)	70	(81.4)				
	Low perceived risk	452	(2.4)	74/336	(22.0)	61	(82.4)				
	Perceived difficulty	865	(4.5)	191/629	(30.4)	124	(64.9)				
	Decline/other reason	249	(1.3)	62/180	(34.4)	43	(69.4)				
Tot	al	19030	(100%)	12152/14501	(83.8)	10314	(84.9)	884	(6.2)	480	(4.3)

Conclusion

A significant minority of SHL users were either ambivalent (11%) or never intended to (11%) return a BBVS blood sample yet 63% and 27% ultimately returned one. Providing blood-sampling equipment in all postal kits and/or exploring a user's intention/rationale around returning a sample may encourage users to test for BBVs. More effort is required to influence and support decision making by e-SHS users who are ambivalent or decline to test for BBVs. Examples that could be implemented and evaluated include: clearer educational messages about the benefits of testing; risk-assessment tools to correct those with mis-placed assumptions; interactive chat-box with a healthcare professional; enhance visual aids and display user journeys or testimonies about the self sampling process.